Why Tesla, PTC Therapeutics, Freeport-McMoRan, and Two More Are in the Spotlight

PTC Therapeutics, Inc. (NASDAQ:PTCT) is 6% in the green after Alethia Young of Credit Suisse upgraded the stock to ‘Outperform’ from ‘Neutral’ and also increased her price target to $25 per share from $15. Due to last week’s CHMP’s positive recommendation, Young thinks PTC’s Translarna will likely be allowed to sell in Europe for at least another four years with no road-bumps. 13 top funds owned shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) at the end of June.

Chico’s FAS, Inc. (NYSE:CHS) and Kohl’s Corporation (NYSE:KSS) have surged 8% and 5%, respectively, after Paul Lejuez of Citi upgraded the two stocks to ‘Buy’ from ‘Neutral’. Like many other sectors, Lejuez believes the two will benefit from Donald Trump becoming President. Specifically, the analyst thinks that Trump’s tax cuts will increase consumer income, which could translate to higher demand for the retailers. Lejuez has a $16 price target on Chico’s, up from the previous $13, and a $64 price target on Kohl’s, up from the previous $50. 28 and 22 funds tracked by Insider Monkey reported bullish positions in Kohl’s Corporation (NYSE:KSS) and Chico’s FAS, Inc. (NYSE:CHS) at the end of the second quarter.

Disclosure:None